Cytos Biotechnology Ltd., of Zurich, Switzerland, appointed Matthias Alder executive vice president for corporate development and legal affairs and named Cheryl Lassen vice president for clinical development

Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., named Bernardino Mosquera vice president of clinical operations...Champions Oncology Inc., of Hackensack, N.J., added Dan Mendelson and Arthur G

AtheroNova Inc., of Irvine, Calif., named Mark K. Wedel senior vice president of clinical affairs and chief medical officer...GeNO LLC, of Waltham, Mass., named Kurt Dasse president and Barry Gellman senior vice president, engineering

Aileron Therapeutics Inc., of Cambridge, Mass., appointed Hubert C. Chen vice president of clinical development...Islet Sciences Inc., of New York, added Kevan Herold and Morton Printz to its scientific advisory board

BioMotiv LLC, of Cleveland, named Baiju R. Shah CEO and board member, effective Sept...Cardio3 BioSciences, of Mont-Saint-Guibert, Belgium, appointed Alexander Milstein vice president of clinical development

Synthetic Biologics Inc., of Ann Arbor, Mich., appointed Jeffrey Kraws independent chairman of the board and Carol Reed senior vice president of clinical and regulatory affairs

Intarcia Therapeutics Inc., of Hayward, Calif., appointed Kurt Graves chairman, president and CEO and Michelle Baron vice president clinical research and chief medical officer

Sangart Inc., of San Diego, promoted Frank Booth to chief medical officer, added Mary Rose Keller as vice president of clinical operations and named Carmen Betancourt-Riche vice president of regulatory affairs and quality assurance...Sirona also appointed Sean Cunliffe chief business officer and board member

GlycoMimetics Inc., of Gaithersburg, Md., promoted Helen Thackray to chief medical officer and vice president of clinical development and named Brian Hahn chief financial officer

It also added John E. Dick and Janet Rossant to its scientific and clinical advisory board...Topica Pharmaceuticals Inc., of Palo Alto, Calif., added Amir Tavakkol as senior vice president of clinical development and operations

NeoStem Inc., of New York, appointed Martyn D. Greenacre and Andrew L. Pecora to the board...NexImmune Inc., of Gaithersburg, Md., appointed Kenneth Carter CEO and named Jonathan Schneck chairman of the clinical and scientific advisory board...Oncolytics Biotech Inc., of Calgary, Alberta, appointed Gerard Kennealey senior vice president of clinical development and chief medical officer

NeoStem Inc., of New York, appointed Martyn D. Greenacre and Andrew L. Pecora to the board...NexImmune Inc., of Gaithersburg, Md., appointed Kenneth Carter CEO and named Jonathan Schneck chairman of the clinical and scientific advisory board...Oncolytics Biotech Inc., of Calgary, Alberta, appointed Gerard Kennealey senior vice president of clinical development and chief medical officer

It also named Robert B. Shapiro and Jeffrey B. Kindler to its board...Medivation Inc., of San Francisco, promoted Sarah Noonberg to vice president of clinical development

Medivir AB, of Huddinge, Sweden, appointed Maris Hartmanis president and CEO...OncoMed Pharmaceuticals Inc., of Redwood City, Calif., appointed Jakob Dupont vice president of clinical research

It also named D. Euan MacIntyre senior vice president of drug discovery and appointed James F. McLeod senior vice president of clinical R&D and chief medical officer

and Jens D. Kristensen as executive vice president of clinical

It also named Timothy D. Kasbe senior vice president and chief information officer...Medicure Inc., of Winnipeg, Manitoba, appointed Dawson Reimer president and chief operating officer...Medivation Inc., of San Francisco, promoted Stewart Hallett to vice president of clinical operations

Seattle Genetics Inc., of Bothell, Wash., appointed Natasha Hernday vice president of corporate development and promoted Eric Sievers vice president of clinical affairs

The firm also nominated Stuart Strathdee and Ganesh Kishore to its board...Novavax Inc., of Rockville, Md., appointed Louis Fries III vice president of clinical and medical affairs and named Jane Halpern vice president of regulatory affairs